Literature DB >> 24366063

Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis.

Zhen Liu1, Jun Zhang2, Lijun Wu2, Jie Liu2, Mingqing Zhang1.   

Abstract

Guanine nucleotide-binding protein (G protein), alpha activating activity polypeptide O (GNAO1) encodes an alpha subunit of the heterotrimeric guanine nucleotide-binding proteins (Gαo), which plays a significant role in the development of various types of cancer, including breast cancer and hepatocellular carcinoma. However, its role in gastric cancer (GC) has not yet been elucidated. In the current study, the expression of Gαo was analyzed by immunohistochemistry in paraffin-embedded tissue sections from 70 patients with GC and its cellular role was examined by small interfering RNA (siRNA)-mediated downregulation. The overexpression of GNAO1 (scores of 2 or 4) was observed in 44 of the 70 patients with GC (62.9%) and the expression of Gαo significantly correlated with the overall survival of the patients with GC after surgery. The median survival rate of patients with a negative or positive expression of Gαo was 61 or 27 months, respectively (P=0.033). The silencing of GNAO1 in GC cells by RNA interference markedly inhibited the proliferation of GC cells and promoted apoptosis by increasing the accumulation of the pro-apoptotic proteins, Puma and Bim, possibly mediated by extracellular signal-regulated kinase 1 and 2 (ERK1/2). This further confirmed the clinical significance of GNAO1, which was overexpressed in GC tissues. To the best of our knowledge, the present study is the first to demonstrate that GNAO1 is overexpressed in GC and that its overexpression correlates with poor prognosis, as it promotes GC cell viability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366063     DOI: 10.3892/ijmm.2013.1598

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment.

Authors:  Yvonne S Ziegler; James J Moresco; Patricia G Tu; John R Yates; Ann M Nardulli
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

2.  Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.

Authors:  Tong Mou; Di Zhu; Xufu Wei; Tingting Li; Daofeng Zheng; Junliang Pu; Zhen Guo; Zhongjun Wu
Journal:  World J Surg Oncol       Date:  2017-03-16       Impact factor: 2.754

3.  Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma.

Authors:  Yang Hua; Xiukun Ma; Xianglong Liu; Xiangfei Yuan; Hai Qin; Xipeng Zhang
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

4.  Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer.

Authors:  Nina Hauptman; Daša Jevšinek Skok; Elena Spasovska; Emanuela Boštjančič; Damjan Glavač
Journal:  BMC Med Genomics       Date:  2019-04-15       Impact factor: 3.063

5.  GNAO1 as a Novel Predictive Biomarker for Late Relapse in Hepatocellular Carcinoma.

Authors:  Meiling Du; Jie Feng; Yiran Tao; Qincong Pan; Fengyuan Chen
Journal:  J Healthc Eng       Date:  2021-11-30       Impact factor: 2.682

6.  Clinical pathologies of breast cancer in the elderly and youths and their prognosis.

Authors:  Hong Ji; Ning Ai; Qinghuai Li; Kaili Zhang; Wang Di
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

7.  Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach.

Authors:  Klemen Zupancic; Andrej Blejec; Ana Herman; Matija Veber; Urska Verbovsek; Marjan Korsic; Miomir Knezevic; Primoz Rozman; Tamara Lah Turnsek; Kristina Gruden; Helena Motaln
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

8.  BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5.

Authors:  Yuan Wang; Xue-Yan Jiang; Xi-Yong Yu
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.